Editor's Note: From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. Over 7,000 hepatology experts from around the world gathered for this academic event. On the first day, the conference focused on various fields including chronic hepatitis B, cirrhosis, and portal hypertension. Hepatology Digest invited two young experts from the Chinese University of Hong Kong, Professor Terry Yip and Dr. Jimmy Che-To Lai, to share their insights and experiences.

Liver biopsy is the "gold standard" for diagnosing liver fibrosis, but due to its high cost, invasive nature, and other disadvantages, it is not widely used. Currently, various non-invasive tests (NITs) based on serum biochemical indicators and/or imaging have been developed to evaluate liver stiffness and diagnose liver fibrosis, aiming to identify high-risk populations early for timely intervention and management. However, the diagnostic performance of various NITs varies, and some diagnostic devices are not easily accessible. Finding an NIT with high accuracy and accessibility is a clinical challenge.

On June 7, 2024, at 5:30 PM in Milan, Italy, the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) jointly released the latest Clinical Practice Guidelines for the management of Metabolic Associated Fatty Liver Disease (MASLD) at the EASL 2024 Annual Meeting. The guidelines cover a wide range of topics from the use of non-invasive diagnostic tools to treatment strategies, emphasizing the importance of treating obesity and diabetes and multidisciplinary collaboration in the management of MASLD. These guidelines have been simultaneously published online in the official journals of EASL, EASD, and EASO, such as the Journal of Hepatology.

From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting took place in the beautiful city of Milan, Italy. Over 7,000 liver disease experts from around the world attended this top-tier academic event. The conference covered a range of diseases including viral hepatitis, metabolic associated fatty liver disease, cirrhosis, liver cancer, and liver failure, presenting the latest clinical research findings in the field. Among the participants, Professor Rui Huang's team from Peking University People's Hospital had two studies accepted for presentation as poster sessions. Their research found that the ratio of visceral fat area to subcutaneous fat area (VSR), sarcopenia, and muscle fat infiltration are independent predictors of liver-related mortality in cirrhosis patients. Additionally, loss of skeletal muscle mass is crucial in predicting liver-related mortality in cirrhosis patients. These findings suggest that actively managing body composition, particularly skeletal muscle mass and visceral and subcutaneous fat content, can help improve prognosis in cirrhosis patients.

On June 5, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting commenced in Milan, Italy, bringing together experts and scholars from the global hepatology field. The conference aimed to share the latest developments and trends in liver disease research, providing valuable references for future research and clinical practice. On the first day of the conference, Academician Gaojun Teng of the Chinese Academy of Sciences and the initiator of the China Diabetes and Liver Disease Management (CDLM) initiative, along with Xiaolong Qi, founder of CHESS and co-initiator of CDLM, presented a novel study. They introduced the DiabetesLiver Score, a non-invasive tool to assess advanced liver fibrosis in type 2 diabetes (T2DM) patients and predict liver-related adverse events.

Transarterial chemoembolization (TACE) is the recommended treatment for intermediate-stage hepatocellular carcinoma (HCC) patients and a viable option for early-stage HCC patients who cannot undergo curative treatments. However, the prognosis for TACE varies significantly among individuals, with objective response rates ranging from 40% to 80% and overall survival times from 13 to 48 months. Given the advancements in molecular targeted therapy and immunotherapy for HCC, accurately predicting individual prognosis and identifying patients with poor prognosis is crucial for optimizing treatment choices and extending survival. On June 6, 2024, at the EASL Annual Meeting in Milan, Professor Guohong Han from Xi'an International Medical Center Hospital in China shared the latest clinical research. Their team developed a predictive model for TACE outcomes, helping guide treatment choices for intermediate HCC patients and improving their survival (Abstract No.: THU-475).